ストックスクリーナーアプリを入手
10.14
1.10%
0.11
アフターアワーズ：
9.98
-0.16
-1.58%
前日終値:
$10.03
開ける：
$9.975
24時間の取引高:
5.53M
Relative Volume:
0.85
時価総額：
$3.15B
収益：
-
当期純損益:
$-124.55M
株価収益率:
-23.08
EPS:
-0.4393
ネットキャッシュフロー:
$-95.58M
1週間 パフォーマンス:
-47.05%
1か月 パフォーマンス:
-43.07%
6か月 パフォーマンス:
+338.96%
1年 パフォーマンス:
+541.77%
1日の値動き範囲:
$9.8141
$10.40
1週間の範囲:
$8.70
$11.24
52週間の値動き範囲:
$1.06
$24.28
Erasca Inc Stock (ERAS) Company Profile
Compare ERAS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
10.14 | 3.12B | 0 | -124.55M | -95.58M | -0.4393 |
VRTX
Vertex Pharmaceuticals Inc
|
429.85 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.21 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.09 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.93 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.14 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 再開されました | Mizuho | Outperform |
| 2026-01-07 | 開始されました | Piper Sandler | Overweight |
| 2025-10-16 | 開始されました | Stifel | Buy |
| 2025-09-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2025-08-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | 開始されました | Raymond James | Outperform |
| 2024-11-18 | 開始されました | Jefferies | Buy |
| 2024-03-11 | 開始されました | CapitalOne | Overweight |
| 2024-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2023-03-30 | 開始されました | Mizuho | Buy |
| 2023-02-24 | 開始されました | Goldman | Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Erasca Inc (ERAS) 最新ニュース
5 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
ERAS stock slumps nearly 40% after-hours: Fine print in 'positive' cancer trial reveals treatment-related death - MSN
Erasca Confronts Trial Fatality And Lawsuit As Valuation Debate Deepens - Sahm
Rambus posts downbeat Q1 earnings, joins Erasca, Spotify, Amkor Technology and other big stocks moving lower in Tuesday's pre-market session - MSN
Clear Street raises Erasca stock price target on combination trial deal - Investing.com
Revolution Medicines Files Patent Infringement Lawsuit Against Erasca - HarianBasis.co
Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity - Insider Monkey
Erasca, Inc. Investigated for Securities Fraud Violations by Block & Leviton - marketscreener.com
Erasca (ERAS) Recoups 16.9% Gain on Cancer Treatment Optimism - Insider Monkey
5 Stocks Delivering Eye-Popping Gains - Insider Monkey
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy - MSN
Rambus Posts Downbeat Q1 Earnings, Joins Erasca, Spotify, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings - Sahm
The Nasdaq Biotechnology Index closed down more than 1.2%. Among its constituent stocks, Tango Therapeutics fell by 12.25%, Personalis dropped 8.36%, PTC Therapeutics decreased by 8.13%, Foghorn slid 8.12%, and Erasca declined 7.98%. - Bitget
ERAS stock slumps against RVMD rally — analyst stays bullish - MSN
Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispu - GuruFocus
Why Erasca Stock Is Tumbling Despite Drug Hopes - TipRanks
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Erasca stock sinks almost 50% after patient death in cancer drug trial - qz.com
Safety concerns arise after the death of a clinical trial participant: Erasca (ERAS.US), a cancer drug developer, sees its stock price halved with a single-day plunge of 48%. - 富途牛牛
Safety concerns arise following the death of a clinical trial participant: Shares of cancer drug developer Erasca (ERAS.US) plummet by 48% in a single day, experiencing a severe drop. - Moomoo
Erasca (ERAS) Valuation Check After Sharp Pullback And Premium Price To Book Ratio - simplywall.st
Erasca (ERAS) Shares Plunge 50% Following Trial Fatality and Patent Dispute - MEXC Exchange
5 Stocks Reeling From Huge Losses - Insider Monkey
Patient Death Drags Erasca (ERAS) Shares by 48% - Insider Monkey
Stock Crash: Cancer drug developer shares plunge 48% after patient dies - CNBC TV18
Boehringer’s obesity drug shows 16.6% weight loss; more data needed - statnews.com
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial - The Motley Fool
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death - Bloomberg.com
Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight (NASDAQ:ERAS) - Seeking Alpha
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off. - Barron's
[ARS] Erasca, Inc. SEC Filing - Stock Titan
Erasca (NASDAQ: ERAS) details 2026 virtual meeting and executive pay - Stock Titan
These Stocks Are Today’s Movers: Oracle, AMD, Intel, Corning, Centene, Erasca, Rambus, Coca-Cola, UPS, and More - Barron's
Erasca (ERAS) Stock Crashes 50% After Patient Death in Cancer Drug Trial - MEXC
Why Erasca, Up 415% This Year Amid Revolution-Tied Furor, Just Lost Half Its Value - Investor's Business Daily
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015Slideshow (NASDAQ:ERAS) 2026-04-28 - Seeking Alpha
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data - marketscreener.com
Erasca (ERAS) Stock Plummets 50% Following Trial Death and Patent Dispute - parameter.io
Erasca shares cut in half after patient death in clinical trial By Investing.com - Investing.com India
Erasca shares cut in half after patient death in clinical trial - Investing.com
Erasca stock sinks 50% in race for pancreatic cancer miracle drug. What’s behind the sell-off? - MSN
Death a sticking point in Erasca molecular glue phase I - BioWorld News
BofA raises Erasca stock price target to $9 on trial data By Investing.com - Investing.com India
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up - BioSpace
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results - BioPharma Dive
Erasca, Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Erasca, Inc. Investigated For Securities Fraud; Block & - GlobeNewswire
ERAS Stock Slides As Legal And Clinical Risks Rattle Traders - StocksToTrade
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday? - Benzinga
High-flying Revolution Medicines threatens to sue a cancer drug competitor with licensed Chinese drug - The Business Journals
Erasca Inc (ERAS) 財務データ
収益
当期純利益
現金流量
EPS
1.90%
大文字化:
|
ボリューム (24 時間):